PremSera® Horse Serum-New Zealand Origin

  • Specification
  • Scientific Data
  • Q & A
  • Customer Review
Cat.No.
CS-006Y
Description
Sera Category: Specialty
Origin: New Zealand
Serum Treatment: Heat-Inactivated
Species: Equine
EIA tested (negative) serum from a donor herd
Recommended for
For In Vitro Diagnostic Use.
Quality Control
Qualified
Storage and Shipping
Storage condition: -5 to -20°C
Shipping: Dry Ice, Frozen
Citation Guidance
If you use this products in your scientific publication, it should be cited in the publication as: Creative Bioarray cat no. If your paper has been published, please click here to submit the PubMed ID of your paper to get a coupon.

Scalable longitudinal imaging and transcriptomics of cells in dynamic enclosures

bioRxiv | DOI | Paper |

Background

The article presents a scalable platform combining light-guided hydrogel polymerization and computer vision to create CellCage Enclosures around live cells. This enables longitudinal imaging of cellular behavior paired with whole-transcriptome profiling of the same cells. In A549 lung cancer cells treated with olmutinib, the platform uncovered a drug-resistant daughter-cell phenotype marked by potassium channel upregulation and p53-dependent quiescence. In adipogenesis and microglial phagocytosis models, integrated imaging and transcriptomics identified functional drivers missed by transcriptomic clustering alone, establishing paired functional and molecular analysis as a new datatype.

Key Findings

The authors developed CellCage Enclosures, photopolymerized hydrogel compartments that allow scalable longitudinal imaging and endpoint 3′ mRNA sequencing of tens of thousands of individual live cells, including adherent cells. They validated reproducible, specific transcriptome capture and demonstrated multi-omic measurement of PBMC responses to LPS. In A549 cells treated with olmutinib, longitudinal imaging combined with transcriptomics revealed four phenotypes, including a daughter-cell-resistant state characterized by sibling cells diverging under drug pressure. This state was linked to potassium channel genes KCNMA1/KCNN4 and p53-dependent quiescence genes (GADD45A, REDD1, ATF3, SFN, BTG2), suggesting a non-mutational adaptive resistance mechanism. In differentiating preadipocytes and BV2 microglia, imaging-derived functional readouts (lipid accumulation, phagocytosis) combined with expression data via elastic net models identified key drivers (e.g., Gpnmb, Clec4e for phagocytosis) that transcriptomic clustering alone missed. The platform thus establishes paired functional imaging and transcriptomics as a powerful approach for resolving molecular drivers of complex cell behaviors.

Contribution

Creative Bioarray provided cell culture reagents—SuperCult Alpha MEM, heat-inactivated FBS, and PremaSera Horse Serum—used to directly culture NK-92 cells. These NK-92 cells were part of the mixed cell-line reproducibility experiment validating transcriptome capture in CellCage Enclosures, supporting platform performance assessment.

Profiling A549 cells following treatment with Olmutinib.
Fig. 1. Profiling A549 cells following treatment with Olmutinib.

Ask a Question

Write your own review

For research use only. Not for any other purpose.

Hot Products